Lilly's Retatrutide Delivered Significant Weight Loss, A1C Reduction In Phase 3 Trial
(RTTNews) - Eli Lilly and Company (LLY) reported detailed Phase 3 TRIUMPH-2 results showing that Retatrutide delivered substantial weight loss and blood sugar reductions in adults with obesity or overweight and type 2 diabetes.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.